相关临床试验
377
90 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
15
4.0%
已完成
116
30.8%
Enrolling By Invitation
9
2.4%
尚未招募
66
17.5%
招募中
110
29.2%
暂停
1
0.3%
终止
11
2.9%
Unknown
45
11.9%
撤回
4
1.1%
暂无批准数据
- Alebund Pharmaceuticals received US FDA clearance of its IND application for AP308, a first-in-class engineered recombinant IgA protease for IgA nephropathy. - AP308 is designed to directly cleave IgA1, galactose-deficient IgA1, polymeric IgA and IgA immune complexes, including deposits already present in the glomeruli. - Preclinical data published in Kidney International showed once-weekly subcutaneous dosing reduced circulating human IgA and IgA immune complexes by roughly 80% in a humanized mouse model. - Alebund plans to initiate a first-in-human Phase I trial in the near term, with global rights to develop, manufacture and commercialize AP308.
- DR10624, a novel triple-receptor agonist targeting FGF21, glucagon, and GLP-1 receptors, demonstrated significant triglyceride reductions of 66-75% across all dose levels in a 12-week Phase II trial. - The investigational drug achieved triglyceride levels below 500 mg/dL in 89.5% of treated patients compared to only 25% of placebo recipients, addressing a challenging clinical condition. - Beyond lipid improvements, DR10624 reduced liver fat content by up to 67%, offering potential benefits for patients with metabolic dysfunction-associated steatotic liver disease. - The medication showed a favorable safety profile with primarily gastrointestinal side effects, though larger and longer-term studies are needed to confirm efficacy and safety.
- Researchers identified four key cellular senescence-related genes (CDKN2A, VEGFA, SOX2, and FOXO3) that could serve as diagnostic biomarkers for idiopathic pulmonary fibrosis (IPF). - A comprehensive bioinformatics analysis of 122 differentially expressed genes revealed that a four-gene model achieved excellent diagnostic performance with an AUC of 0.956 in the training dataset. - The study validated these findings using immunofluorescence staining on lung tissue samples from IPF patients, confirming differential expression patterns compared to healthy controls. - These cellular senescence-related biomarkers could provide new insights into IPF pathogenesis and potentially guide development of senescence-based therapeutic interventions.
- Everest Medicines presented positive Phase 1b/2a trial results for EVER001, a next-generation covalent reversible BTK inhibitor, showing significant efficacy in treating primary membranous nephropathy at the 62nd European Renal Association Congress. - The trial demonstrated substantial reductions in anti-PLA2R autoantibodies (up to 93% at week 24) and proteinuria (78% reduction sustained through week 52 in low-dose cohort), with favorable safety profile and no serious adverse events associated with earlier BTK inhibitors. - EVER001 addresses a critical unmet medical need as no drugs are currently approved globally for primary membranous nephropathy, which affects approximately 2.2 million patients worldwide and represents the second most common cause of primary glomerulonephritis.
- A comprehensive meta-analysis of 34 randomized controlled trials involving 2,976 participants has validated the efficacy of Si-Shen-Wan (SSW) in treating diarrhea-predominant irritable bowel syndrome. - The traditional Chinese medicine formula demonstrated significant improvements in multiple symptom scores including abdominal pain, diarrhea, abdominal distension, and loss of appetite in IBS-D patients. - Researchers from leading Chinese medical institutions employed trial sequential analysis to ensure robust findings, potentially offering a valuable alternative treatment for this common functional gastrointestinal disorder.
- VivaVision Biotech's dual JAK1/TYK2 inhibitor VVN461 demonstrated non-inferior efficacy to prednisolone acetate in treating non-infectious anterior uveitis in a Phase 2 trial conducted across 10 clinical sites in China. - Both 0.5% and 1.0% concentrations of VVN461 showed statistically significant improvements in anterior chamber cell grade with no substantial treatment-related adverse events, suggesting a potentially safer alternative to corticosteroids. - The company plans to discuss Phase 3 clinical trials with Chinese regulatory authorities and request a type C meeting with the FDA, potentially advancing a new non-steroidal treatment option for the estimated 3 million uveitis patients in China.
